Effects of TS-1 on peritoneal dissemination of gastric cancer in nude mice.
OBJECTIVE
We investigated the effects of TS-1 on the survival of nude mice developing peritoneal dissemination of gastric cancer.


METHODS
MKN-45 cells were injected into the peritoneal cavity of nude mice and a model of peritoneal dissemination was developed. TS-1 was administered orally every day from day 1 to day 10 or day 10 to day 19.


RESULTS
Survival time of these treatment groups was significantly longer than untreated controls. In a pharmacokinetic study, TS-1 was administered on day 10 and the 5-fluorouracil levels were retained and maintained for a longer time, in the ascites and tumor than in plasma. The area under the concentration curve for 5-FU in the tumor was higher, than in plasma or ascites.


CONCLUSIONS
TS-1 could be effective in treating peritoneal dissemination of gastric cancer, due to the supply of 5-fluorouracil in the tumor by systemic and intraperitoneal circulation.
Yoshikawa
Takaki
T
Department of Gastrointestinal Surgery, Research Institute Kanagawa Cancer Center, Yokohama City Kowan Hospital, Yokohama, Japan.
Yanoma
Shunsuke
S
Tsuburaya
Akira
A
Kobayashi
Osamu
O
Sairenji
Motonori
M
Motohashi
Hisahiko
H
Hasegawa
Shinichi
S
Ishiwa
Naoki
N
Morinaga
Soichiro
S
Noguchi
Yoshikazu
Y
Yamamoto
Yuji
Y
Matsumoto
Akihiko
A
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D001682:Biological Availability; D045744:Cell Line, Tumor / Q000473:pathology; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000097:blood; D004347:Drug Interactions; D005472:Fluorouracil / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000556:secondary*; D010537:Peritoneum / Q000473:pathology; D017640:Silicates / Q000494:pharmacology*; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000473:pathology*; D016019:Survival Analysis; D014025:Titanium / Q000494:pharmacology*
D000970:Antineoplastic Agents; D017640:Silicates; C103828:titanium silicide; D014025:Titanium; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil